Timothy Cooke, Ph.D.
Chief Executive Officer
Dr. Cooke joined NovaDigm Therapeutics as Chief Executive Officer in 2009. He has broad leadership experience in both emerging and large multinational companies in the fields of vaccines and immunotherapeutics. Dr. Cooke joined Merck when it launched a dedicated vaccine business unit in 1991 and over the next nine years was a key contributor to establishing a global sales and marketing organization. He was also a founding member of Sanofi Pasteur-MSD, a European joint venture between Sanofi Pasteur and Merck. Dr. Cooke was the Chief Executive Officer of Mojave Therapeutics, a company developing therapeutic vaccines against viral infections and cancer, which was sold to Antigenics in 2004. He was most recently Chief Operating Officer of AVANT Immunotherapeutics prior to its acquisition by CellDex Therapeutics in 2008. Dr. Cooke has a bachelor’s degree from Saint Joseph’s University, and a Ph.D. in bio-organic chemistry and an M.B.A. from Columbia University.
Dr. Cooke is currently the biotechnology industry representative to the National Vaccine Advisory Committee of the Department of Health and Human Services and was previously Co-Chair of the Biotechnology Innovation Organization’s Vaccine Policy Advisory Committee.
John P. Hennessey, Jr., Ph.D.
Chief Scientific Officer
Dr. Hennessey joined NovaDigm Therapeutics as Vice President, Research & Development in 2009. He has over twenty years of vaccine and biologics development experience, with a primary focus on the chemistry, manufacturing and control (CMC) aspects of product development. Much of his past efforts have been focused on process, analytical and formulation development of vaccine products in preclinical as well as early- and late-stage clinical development. He joined Merck & Co., Inc. in 1989 and became a key leader for development, technology transfer and licensure of five new vaccines as well as three second generation vaccines. Additionally, he was integral to the preclinical and clinical development of a wide variety of vaccine and biologics programs and provided post-licensure technical support for several commercial vaccines. He has co-authored over 30 peer-reviewed articles, many related specifically to vaccine development activities, and three book chapters, is a co-inventor on eight patents and has given invited presentations at over 35 national and international conferences.
Chief Business Officer
Tuomas joined NovaDigm Therapeutics in 2006 as a co-founder. He is a serial entrepreneur with diverse experience managing and mentoring companies in early stages of development. At NovaDigm, Tuomas has played key roles in developing and managing the investor and government relationships, recruiting the management team, and in building the company. Tuomas received his MBA from the University of Southern California, Marshall School of Business. He received his Bachelor of Science in Applied Physics from the California Institute of Technology (Caltech).